- HKSH Medical Group hosts the 5th Annual PTCOG-AO Conference in Hong Kong from 7-9 November 2025, marking the city’s first global proton therapy event.
- The conference gathers 30+ international proton therapy experts and 400+ participants, focusing on precision, image-guided particle therapy, and latest clinical advancements.
- HKSH, the first in Hong Kong and Greater Bay Area to launch a proton therapy system, aims to advance regional cancer treatment standards and foster knowledge exchange.
HKSH Medical Group (HKSH) reached a milestone in 2023 with the commissioning of Hong Kong's first and Greater Bay Area's first proton therapy system after more than two decades of planning and preparation. Two years since its opening, the HKSH Proton Therapy Centre has established itself as one of the top centers for precision cancer treatment, having treated more than 500 patients and gained rich clinical experience.
Based on this, HKSH jointly hosted the 'Proton Therapy Joint Training Course' with Beijing's National Cancer Center in June, followed by the ten-month 'HKSH Cancer Centre Proton Therapy Training Programme' that was launched in August and that is designed to cultivate highly trained professionals in proton therapy. These efforts pave the way for HKSH to be the venue for the 5th Annual Conference of the Asia-Oceania Particle Therapy Co-operative Group (PTCOG-AO) from 7 to 9 November 2025, the first world landmark event of its kind in Hong Kong.
The three-day PTCOG-AO Conference, held at the Hong Kong Convention and Exhibition Centre and HKSH Proton Therapy Centre, will be on 'Advancing Particle Therapy with Greater Precision and Image-Guidance'. Sponsored by the Hong Kong Tourism Board, InvestHK, and close to 30 key regional healthcare entities, the conference will include seminars, lectures by experts, clinical demonstrations, and presentations of the newest proton therapy technologies.
Participants will be enlightened about novel methods in precision cancer therapy, as international experts exchange clinical experience and best practices to raise medical standards and quality of care for patients. Industry partners will also present state-of-the-art particle therapy innovations and solutions to complement HKSH's dedication to refining cancer treatment.
Also Read: The Role of Generative AI in Medical Education
Mr. Wyman Li, Chief Operating Officer of HKSH Medical Group and Director of the Li Shu Fan Medical Foundation, underscored HKSH's commitment to advancing medical education, research, and charity while providing top-notch healthcare services and innovation for public good. Having seen the value of talent and technology, HKSH invested in training its medical specialists at the Mayo Clinic in America to establish a multidisciplinary proton therapy team, with a high level of care for patients. With the integration of training programs and the PTCOG-AO Conference, HKSH aims to bring clinical know-how together with worldwide views, providing a platform for ongoing learning and professional development in the Asia-Pacific region.
The PTCOG-AO 2025 will host more than 30 of the world's top proton therapy professionals and over 400 attendees, including academic scientists, clinicians, radiation therapy professionals, and medical physicists from nations like China, Japan, Taiwan, South Korea, the US, and Germany. Keynote speakers are Prof. Marco Durante of the GSI Helmholtz Centre for Heavy Ion Research in Germany and Prof. Tatsuya Ohno of Gunma University Heavy Ion Medical Center in Japan.
The meeting will address clinical case presentations for all major cancer types, such as head and neck, breast, central nervous system, gastrointestinal, genitourinary, non-small cell lung, and pediatric cancers, as well as the application of advanced imaging modalities like CT and MRI for treatment planning.
Chairman of the Organizing Committee, Dr. Simon Tang, said that PTCOG-AO 2025 hosting is a testament to HKSH's commitment to promoting regional cooperation, improving proton therapy standards, and enhancing cancer treatment outcomes. With this high-profile congress, HKSH hopes to offer an innovative platform for information exchange, promote particle therapy innovation, and advance precision cancer care in Hong Kong and the Greater Bay Area.
